Acceptance of Bexmarilimab Data for Oral Presentation at 2025 Annual MDS Foundation Congress
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your FARN notes
| Faron Pharmaceuticals Ltd | Press Release | March 27, 2025 at 09:00:00 EET |
New analysis and biomarker data strengthens understanding of bexmarilimab’s potential
TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, today announces that data from its ongoing BEXMAB study evaluating bexmarilimab in patients with high-risk myelodysplastic syndromes (HR-MDS) have been accepted for an oral presentation on May 10th in a plenary session at the 18th International Congress on Myelodysplastic Syndromes (MDS 2025), taking place on May 7-10, 2025 in Rotterdam, Netherlands.
The oral presentation will feature updated clinical results from the BEXMAB study, including data previously presented at the ASH Annual Meeting 2024, now analyzed with the International Working Group (IWG) 2023 response criteria. Additionally, the presentation will include updated bone marrow Clever-1 expression biomarker data, further elucidating bexmarilimab’s mechanism of action and its potential in improving outcomes for patients with refractory or relapsed MDS who have failed hypomethylating agent (HMA) therapies (r/r MDS).
- Petri Bono, Chief Medical Officer of Faron Pharmaceuticals, said: “Patients with relapsed or refractory high-risk MDS have very limited treatment options, and the need for novel, effective therapies is urgent. The data we are presenting at MDS 2025 incorporates the latest IWG 2023 response criteria and biomarker insights, which strengthens our understanding of bexmarilimab’s potential to modulate the immune system and improve patient outcomes. These findings bring us another step closer to the possibility of offering a meaningful new treatment approach for this devastating disease.”
The details of the oral presentation are as follows:
Presentation title: Preliminary efficacy of bexmarilimab with azacitidine in relapsed or refractory MDS in BEXMAB Ph1/2 study
Session: Plenary Session 08: Treatment high risk
Presenter: Dr. Amer Zeidan, MBBS, MHS
Date and Time: 10th May 2025, 09:50 - 11:20
Location: Rotterdam, Netherlands
Abstract no: 225
Further details will be shared closer to the conference dates.
About bexmarilimab
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.